Source: Drug Development Research. Unidades: FCFRP, FMRP
Subjects: ANTIVIRAIS, COVID-19, CORONAVIRUS, INTERLEUCINA 6
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FUZO, Carlos Alessandro et al. Celastrol: a lead compound that inhibits SARS-CoV-2 replication, the activity of viral and human cysteine proteases, and virus-induced IL-6 secretion. Drug Development Research, v. 83, n. 7, p. 1623-1640, 2022Tradução . . Disponível em: https://doi.org/10.1002/ddr.21982. Acesso em: 01 nov. 2024.APA
Fuzo, C. A., Martins Júnior, R. B., Fraga-Silva, T. F. de C., Amstalden, M. K., Leo, T. C. de, Souza, J. P., et al. (2022). Celastrol: a lead compound that inhibits SARS-CoV-2 replication, the activity of viral and human cysteine proteases, and virus-induced IL-6 secretion. Drug Development Research, 83( 7), 1623-1640. doi:10.1002/ddr.21982NLM
Fuzo CA, Martins Júnior RB, Fraga-Silva TF de C, Amstalden MK, Leo TC de, Souza JP, Lima TM de, Faccioli LH, Okamoto DN, Juliano MA, França SC, Juliano L, Bonato VLD, Arruda Neto E de, Dias-Baruffi M. Celastrol: a lead compound that inhibits SARS-CoV-2 replication, the activity of viral and human cysteine proteases, and virus-induced IL-6 secretion [Internet]. Drug Development Research. 2022 ; 83( 7): 1623-1640.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1002/ddr.21982Vancouver
Fuzo CA, Martins Júnior RB, Fraga-Silva TF de C, Amstalden MK, Leo TC de, Souza JP, Lima TM de, Faccioli LH, Okamoto DN, Juliano MA, França SC, Juliano L, Bonato VLD, Arruda Neto E de, Dias-Baruffi M. Celastrol: a lead compound that inhibits SARS-CoV-2 replication, the activity of viral and human cysteine proteases, and virus-induced IL-6 secretion [Internet]. Drug Development Research. 2022 ; 83( 7): 1623-1640.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1002/ddr.21982